Frontlight ResearchEarly access
CompletedNo phase
A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder
Key facts
- Who runs it
- The University of Texas Health Science Center, Houston
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 14 people enrolled
- Started
- 31 Mar 2025
- Ended
- 15 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- EFT
- high frequency rTMS
- sham frequency rTMS
- Record updated
- 24 September 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for primary methamphetamine use disorder
- Be fluent in English and able to understand the consent form
Who cannot take part
- Medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps, electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil)
- Current DSM-5 diagnosis for any illicit substance use disorder other than methamphetamine and marijuana
- Current DSM-5 diagnosis of moderate or greater severity for alcohol and marijuana use disorder
- In the opinion of the PI, the presence of any medical, neurological, psychiatric (e.g., psychotic or bipolar disorder), or physical condition, disease, or illness that, may: (a) compromise, interfere, limit, effect or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data
- History of brain surgery
- History of an intracranial lesion or any medical or neurological diagnosis/condition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension/Pseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches > 15 days/month, loss of vision or decreased vision
- Moderate-to-severe heart disease
- History of stroke
- Is taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the PI; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:; clozapine; chlorpromazine; bupropion; clomipramine hydrochloride; amoxapine; maprotiline hydrochloride; diphenhydramine; stimulants other than methamphetamine including the following: Dextroamphetamine and amphetamine, Dextroamphetamine, Lisdexamfetamine dimesylate, Cocaine, Methylphenidate,; tramadol; isoniazid
- Personal history of epilepsy or seizure disorder and/or family history including a first-degree relative
- For adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope/presyncope related to noxious stimuli, anxiety, micturition, or posture)
- Has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments according to the PI:; Structured Clinical Interview for DSM-5 (SCID-5); Columbia-Suicide Severity Rating Scale (C-SSRS) Screening - Answers YES to Questions 3, 4, 5, or 6; Assault \& homicidal danger assessment tool - Key to danger >1
- Serious head injury with loss of consciousness
- Impending incarceration
- Pregnant or nursing females
- Inability to read, write, or speak English
Where in United States
- The University of Texas Health Science Center at HoustonHouston, United States
About the trial
What the trial wants to find out
The purpose of this study is to assess impact of repetitive transcranial magnetic stimulation (rTMS)+Episodic Future Thinking (EFT) vs. sham rTMS+EFT on delay discounting and methamphetamine (MA) demand, on vividness of future positive events during EFT training and on frequency of episodic thinking during the week following EFT training
The 2 groups in the trial
- highfrequency rTMS+EFTTreatment being tested
Treatment: EFT and high frequency rTMS
- sham rTMS+EFTSham treatment, for comparison
Treatment: EFT and sham frequency rTMS
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 24 September 2026